Mushtaq Khan
Hospitalist · Los Angeles, CANPI 1407920333
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $908, 2.5 times the $363 reported in 2019. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$439
- Sunovion Pharmaceuticals Inc.$407
- GSK$265
- Bayer$245
- Gilead$145
- Vanda Pharmaceuticals Inc.$132
- plus $1K from 18 others
Across 3 payments — averaging $3663.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$11K
What the payments were for
- Food & beverage$2,738100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 24 | $439 |
| Sunovion Pharmaceuticals Inc. | 34 | $407 |
| GSK | 14 | $265 |
| Bayer | 11 | $245 |
| Gilead | 6 | $145 |
| Vanda Pharmaceuticals Inc. | 6 | $132 |
| Johnson & Johnson | 4 | $126 |
| Novo Nordisk | 7 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $118 |
| AstraZeneca | 6 | $111 |
| Novartis | 4 | $104 |
| Alkermes, Inc. | 5 | $101 |
| Teva Pharmaceuticals USA, Inc. | 4 | $87 |
| AbbVie | 3 | $56 |
| Lilly USA, LLC | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $44 |
| Pfizer | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$2,738 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 158 | $95,084 |
| Zileuton ErZileuton | 22 | $81,315 |
| Diclofenac Sodium | 37 | $41,659 |
| KerendiaFinerenone | 55 | $35,673 |
| JardianceEmpagliflozin | 55 | $34,623 |
| FarxigaDapagliflozin Propanediol | 47 | $27,088 |
| RybelsusSemaglutide | 25 | $24,191 |
| EliquisApixaban | 31 | $20,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $17,767 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,298 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 222 | $9,533 |
| TradjentaLinagliptin | 15 | $8,688 |
| LinzessLinaclotide | 15 | $7,562 |
| VascepaIcosapent Ethyl | 19 | $6,391 |
| Repatha SureclickEvolocumab | 11 | $5,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $111 | $44,38674 claims |
| Boehringer IngelheimJardiance, Tradjenta | $44 | $43,31170 claims |
| BayerKerendia | $245 | $35,67355 claims |
| Novo NordiskRybelsus | $122 | $24,19125 claims |
| PfizerEliquis | $27 | $20,82431 claims |
| GSKTrelegy Ellipta | $265 | $17,76728 claims |
| AbbVieLinzess | $56 | $7,56215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Los Angeles
- Edward LeeLos Angeles$30K
- Pooya BanankhahLos Angeles$3K
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Anjani KolahiOrange$30K
- Omar AldaasSan Diego$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.